Alberto Bardelli

Alberto Bardelli Alberto Bardelli (born 29 November 1967) is an Italian geneticist and cancer researcher, expert in the field of precision medicine. He is a full professor of histology at the Department of Oncology, University of Turin and Scientific Director of IFOM, the AIRC Institute of Molecular Oncology. Provided by Wikipedia
Showing 1 - 20 results of 41 for search 'Alberto Bardelli', query time: 0.06s Refine Results
  1. 1
    Inactivation of DNA repair—prospects for boosting cancer immune surveillance

    Inactivation of DNA repair—prospects for boosting cancer immune surveillance by Anna Truini, Giovanni Germano, Alberto Bardelli

    Published 2018-11-01
    Get full text
    Article
  2. 2
    Activation of β-catenin by oncogenic PIK3CA and EGFR promotes resistance to glucose deprivation by inducing a strong antioxidant response.

    Activation of β-catenin by oncogenic PIK3CA and EGFR promotes resistance to glucose deprivation by inducing a strong antioxidant response. by Luca Cardone, Alberto Bardelli, Vittorio Enrico Avvedimento

    Published 2012-01-01
    Get full text
    Article
  3. 3
    Early‐onset colorectal cancer in young individuals

    Early‐onset colorectal cancer in young individuals by Gianluca Mauri, Andrea Sartore‐Bianchi, Antonio‐Giampiero Russo, Silvia Marsoni, Alberto Bardelli, Salvatore Siena

    Published 2019-02-01
    Get full text
    Article
  4. 4
    Mutational profiling of kinases in human tumours of pancreatic origin identifies candidate cancer genes in ductal and ampulla of vater carcinomas.

    Mutational profiling of kinases in human tumours of pancreatic origin identifies candidate cancer genes in ductal and ampulla of vater carcinomas. by Vincenzo Corbo, Rossana Ritelli, Stefano Barbi, Niccola Funel, Daniela Campani, Alberto Bardelli, Aldo Scarpa

    Published 2010-09-01
    Get full text
    Article
  5. 5
    Mechanisms of Immune Escape and Resistance to Checkpoint Inhibitor Therapies in Mismatch Repair Deficient Metastatic Colorectal Cancers

    Mechanisms of Immune Escape and Resistance to Checkpoint Inhibitor Therapies in Mismatch Repair Deficient Metastatic Colorectal Cancers by Vito Amodio, Gianluca Mauri, Nicole M. Reilly, Andrea Sartore-Bianchi, Salvatore Siena, Alberto Bardelli, Giovanni Germano

    Published 2021-05-01
    Get full text
    Article
  6. 6
    Loss of AXIN1 drives acquired resistance to WNT pathway blockade in colorectal cancer cells carrying RSPO3 fusions

    Loss of AXIN1 drives acquired resistance to WNT pathway blockade in colorectal cancer cells carrying RSPO3 fusions by Gabriele Picco, Consalvo Petti, Alessia Centonze, Erica Torchiaro, Giovanni Crisafulli, Luca Novara, Andrea Acquaviva, Alberto Bardelli, Enzo Medico

    Published 2017-03-01
    Get full text
    Article
  7. 7
    Inhibition of Heme Export and/or Heme Synthesis Potentiates Metformin Anti-Proliferative Effect on Cancer Cell Lines

    Inhibition of Heme Export and/or Heme Synthesis Potentiates Metformin Anti-Proliferative Effect on Cancer Cell Lines by Anna Lucia Allocco, Francesca Bertino, Sara Petrillo, Deborah Chiabrando, Chiara Riganti, Alberto Bardelli, Fiorella Altruda, Veronica Fiorito, Emanuela Tolosano

    Published 2022-02-01
    Get full text
    Article
  8. 8
    Corrigendum: Case report: MAP2K1 K57N mutation is associated with primary resistance to anti-EGFR monoclonal antibodies in metastatic colorectal cancer

    Corrigendum: Case report: MAP2K1 K57N mutation is associated with primary resistance to anti-EGFR monoclonal antibodies in metastatic colorectal cancer by Gianluca Mauri, Gianluca Mauri, Gianluca Mauri, Giorgio Patelli, Giorgio Patelli, Viviana Gori, Viviana Gori, Calogero Lauricella, Benedetta Mussolin, Alessio Amatu, Katia Bencardino, Federica Tosi, Erica Bonazzina, Emanuela Bonoldi, Alberto Bardelli, Alberto Bardelli, Salvatore Siena, Salvatore Siena, Andrea Sartore-Bianchi, Andrea Sartore-Bianchi

    Published 2023-03-01
    Get full text
    Article
  9. 9
    Case Report: MAP2K1 K57N mutation is associated with primary resistance to anti-EGFR monoclonal antibodies in metastatic colorectal cancer

    Case Report: MAP2K1 K57N mutation is associated with primary resistance to anti-EGFR monoclonal antibodies in metastatic colorectal cancer by Gianluca Mauri, Gianluca Mauri, Gianluca Mauri, Giorgio Patelli, Giorgio Patelli, Viviana Gori, Viviana Gori, Calogero Lauricella, Benedetta Mussolin, Alessio Amatu, Katia Bencardino, Federica Tosi, Erica Bonazzina, Emanuela Bonoldi, Alberto Bardelli, Alberto Bardelli, Salvatore Siena, Salvatore Siena, Andrea Sartore-Bianchi, Andrea Sartore-Bianchi

    Published 2022-11-01
    Get full text
    Article
  10. 10
    Case report: Preclinical efficacy of NEDD8 and proteasome inhibitors in patient-derived models of signet ring high-grade mucinous colorectal cancer from a Lynch syndrome patient

    Case report: Preclinical efficacy of NEDD8 and proteasome inhibitors in patient-derived models of signet ring high-grade mucinous colorectal cancer from a Lynch syndrome patient by Erica Torchiaro, Consalvo Petti, Sabrina Arena, Sabrina Arena, Francesco Sassi, Giorgia Migliardi, Alfredo Mellano, Roberta Porporato, Marco Basiricò, Loretta Gammaitoni, Enrico Berrino, Enrico Berrino, Monica Montone, Giorgio Corti, Giovanni Crisafulli, Caterina Marchiò, Caterina Marchiò, Alberto Bardelli, Alberto Bardelli, Enzo Medico, Enzo Medico

    Published 2023-02-01
    Get full text
    Article
  11. 11
    Codon bias imposes a targetable limitation on KRAS-driven therapeutic resistance

    Codon bias imposes a targetable limitation on KRAS-driven therapeutic resistance by Moiez Ali, Erin Kaltenbrun, Grace R. Anderson, Sarah Jo Stephens, Sabrina Arena, Alberto Bardelli, Christopher M. Counter, Kris C. Wood

    Published 2017-06-01
    Get full text
    Article
  12. 12
    RAF Suppression Synergizes with MEK Inhibition in KRAS Mutant Cancer Cells

    RAF Suppression Synergizes with MEK Inhibition in KRAS Mutant Cancer Cells by Simona Lamba, Mariangela Russo, Chong Sun, Luca Lazzari, Carlotta Cancelliere, Wipawadee Grernrum, Cor Lieftink, Rene Bernards, Federica Di Nicolantonio, Alberto Bardelli

    Published 2014-09-01
    Get full text
    Article
  13. 13
    KRAS mutations testing in colorectal carcinoma patients in Italy: from guidelines to external quality assessment.

    KRAS mutations testing in colorectal carcinoma patients in Italy: from guidelines to external quality assessment. by Nicola Normanno, Carmine Pinto, Francesca Castiglione, Alberto Bardelli, Marcello Gambacorta, Gerardo Botti, Oscar Nappi, Salvatore Siena, Fortunato Ciardiello, Gianluigi Taddei, Antonio Marchetti

    Published 2011-01-01
    Get full text
    Article
  14. 14
    Absence of AKT1 mutations in glioblastoma.

    Absence of AKT1 mutations in glioblastoma. by Fonnet E Bleeker, Simona Lamba, Carlo Zanon, Angela A van Tilborg, Sieger Leenstra, Dirk Troost, Theo Hulsebos, W Peter Vandertop, Alberto Bardelli

    Published 2009-05-01
    Get full text
    Article
  15. 15
    Non-canonical antigens are the largest fraction of peptides presented by MHC class I in mismatch repair deficient murine colorectal cancer

    Non-canonical antigens are the largest fraction of peptides presented by MHC class I in mismatch repair deficient murine colorectal cancer by Giuseppe Rospo, Rosaria Chilà, Vittoria Matafora, Veronica Basso, Simona Lamba, Alice Bartolini, Angela Bachi, Federica Di Nicolantonio, Anna Mondino, Giovanni Germano, Alberto Bardelli

    Published 2024-01-01
    Get full text
    Article
  16. 16
    Correction: Correction: CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours.

    Correction: Correction: CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours. by Sara Costa-Cabral, Rachel Brough, Asha Konde, Marieke Aarts, James Campbell, Eliana Marinari, Jenna Riffell, Alberto Bardelli, Christopher Torrance, Christopher J Lord, Alan Ashworth

    Published 2018-01-01
    Get full text
    Article
  17. 17
    Correction: CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours.

    Correction: CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours. by Sara Costa-Cabral, Rachel Brough, Asha Konde, Marieke Aarts, James Campbell, Eliana Marinari, Jenna Riffell, Alberto Bardelli, Christopher Torrance, Christopher J Lord, Alan Ashworth

    Published 2017-01-01
    Get full text
    Article
  18. 18
    CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours.

    CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours. by Sara Costa-Cabral, Rachel Brough, Asha Konde, Marieke Aarts, James Campbell, Eliana Marinari, Jenna Riffell, Alberto Bardelli, Christopher Torrance, Christopher J Lord, Alan Ashworth

    Published 2016-01-01
    Get full text
    Article
  19. 19
    Correction: CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours.

    Correction: CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours. by Sara Costa-Cabral, Rachel Brough, Asha Konde, Marieke Aarts, James Campbell, Eliana Marinari, Jenna Riffell, Alberto Bardelli, Christopher Torrance, Christopher J Lord, Alan Ashworth

    Published 2016-01-01
    Get full text
    Article
  20. 20
    Mutational profile of GNAQQ209 in human tumors.

    Mutational profile of GNAQQ209 in human tumors. by Simona Lamba, Lara Felicioni, Fiamma Buttitta, Fonnet E Bleeker, Sara Malatesta, Vincenzo Corbo, Aldo Scarpa, Monica Rodolfo, Margaret Knowles, Milo Frattini, Antonio Marchetti, Alberto Bardelli

    Published 2009-08-01
    Get full text
    Article

Search Tools: